| pubmed-article:1726206 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1726206 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:1726206 | lifeskim:mentions | umls-concept:C0149725 | lld:lifeskim |
| pubmed-article:1726206 | lifeskim:mentions | umls-concept:C0108938 | lld:lifeskim |
| pubmed-article:1726206 | pubmed:dateCreated | 1992-7-8 | lld:pubmed |
| pubmed-article:1726206 | pubmed:abstractText | Cefpodoxime proxetil is the orally absorbed ester of cefpodoxime, a new third generation cephalosporin. In the gastrointestinal tract, cefpodoxime proxetil is hydrolysed to cefpodoxime, which has potent antibacterial activity against the major bacterial pathogens involved in lower respiratory tract infections: Haemophilus influenzae, Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains), and Streptococcus pneumoniae (including amoxicillin-resistant strains). Six randomised comparative studies in patients with lower respiratory tract infections, 5 of which were large (enrollment of more than 200 patients) and double-blind, examined the efficacy and safety of cefpodoxime proxetil. Cefpodoxime proxetil (at a dosage equivalent to 200mg of cefpodoxime) administered twice daily for 5 to 10 days was similar in clinical and bacteriological efficacy to the following: amoxicillin 500mg 3 times daily in the treatment of community-acquired pneumonia; intramuscular ceftriaxone Ig once daily in the treatment of pulmonary infections in hospitalised patients; and to amoxicillin/clavulanic acid 500/125mg 3 times daily in the treatment of acute exacerbations of chronic bronchitis (AECB). Additionally, a dosage equivalent to 100mg or 200mg of cefpodoxime twice daily was similar in clinical and bacteriological efficacy to amoxicillin 250mg 3 times daily in the treatment of bronchitis (acute or AECB). The adverse events noted with cefpodoxime proxetil administration were similar to those associated with other beta-lactam antibacterials and most commonly involved the gastrointestinal tract and skin or mucous membranes. Thus, cefpodoxime proxetil is a useful addition to the antibacterials available for the treatment of infections of the lower respiratory tract. | lld:pubmed |
| pubmed-article:1726206 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1726206 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1726206 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1726206 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1726206 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1726206 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1726206 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1726206 | pubmed:issn | 0012-6667 | lld:pubmed |
| pubmed-article:1726206 | pubmed:author | pubmed-author:GeddesA MAM | lld:pubmed |
| pubmed-article:1726206 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1726206 | pubmed:volume | 42 Suppl 3 | lld:pubmed |
| pubmed-article:1726206 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1726206 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1726206 | pubmed:pagination | 34-40 | lld:pubmed |
| pubmed-article:1726206 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:1726206 | pubmed:meshHeading | pubmed-meshheading:1726206-... | lld:pubmed |
| pubmed-article:1726206 | pubmed:meshHeading | pubmed-meshheading:1726206-... | lld:pubmed |
| pubmed-article:1726206 | pubmed:meshHeading | pubmed-meshheading:1726206-... | lld:pubmed |
| pubmed-article:1726206 | pubmed:meshHeading | pubmed-meshheading:1726206-... | lld:pubmed |
| pubmed-article:1726206 | pubmed:meshHeading | pubmed-meshheading:1726206-... | lld:pubmed |
| pubmed-article:1726206 | pubmed:meshHeading | pubmed-meshheading:1726206-... | lld:pubmed |
| pubmed-article:1726206 | pubmed:meshHeading | pubmed-meshheading:1726206-... | lld:pubmed |
| pubmed-article:1726206 | pubmed:meshHeading | pubmed-meshheading:1726206-... | lld:pubmed |
| pubmed-article:1726206 | pubmed:meshHeading | pubmed-meshheading:1726206-... | lld:pubmed |
| pubmed-article:1726206 | pubmed:meshHeading | pubmed-meshheading:1726206-... | lld:pubmed |
| pubmed-article:1726206 | pubmed:meshHeading | pubmed-meshheading:1726206-... | lld:pubmed |
| pubmed-article:1726206 | pubmed:meshHeading | pubmed-meshheading:1726206-... | lld:pubmed |
| pubmed-article:1726206 | pubmed:meshHeading | pubmed-meshheading:1726206-... | lld:pubmed |
| pubmed-article:1726206 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1726206 | pubmed:articleTitle | Cefpodoxime proxetil in the treatment of lower respiratory tract infections. | lld:pubmed |
| pubmed-article:1726206 | pubmed:affiliation | Department of Communicable and Tropical Diseases, East Birmingham Hospital, England. | lld:pubmed |
| pubmed-article:1726206 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1726206 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:1726206 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:1726206 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1726206 | lld:pubmed |
